Amyotrophic lateral sclerosis: new era, new challenges

Lu Tang,Dongsheng Fan

DOI: https://doi.org/10.1016/S1474-4422(22)00084-9

2022-01-01

Abstract:Amyotrophic lateral sclerosis is a rare but fatal neurodegenerative disease, that typically leads to muscle within 2???4 years after symptom onset. A Series of two papers in The Lancet Neurology1,2 review the latest advances in amyotrophic lateral sclerosis research, providing an updated overview of its genetic architecture, pathophysiology, diagnosis, and prognosis. The ultimate challenge for research lies in the dearth of effective treatments. Two therapies, riluzole and edaravone, have been approved in several countries. However, riluzole was shown to prolong survival by only 2???3 months,3 whereas edaravone slowed the rate of functional loss by 33% over 24 weeks, as measured by the Scale (ALSFRS-R) in the MCI-186 Study 19.4 The first phase 3 trial (MCI-186 Study 16) did not show efficacy of edaravone in slowing the progression of amyotrophic lateral sclerosis.5 However, a post-hoc analysis and subsequent extension studies revealed an efficacyexpected subpopulation (EESP) thought to benefit from edaravone. A machine-learning model recently showed a significant treatment effect with edaravone in a cohort with a broader range of features than that in the EESP.6 However, a prospective multicentre cohort study in Germany, which included three times the number of patients than the MCI-186 Study 19, found no differences in any disease-modifying benefit between long-term (ie, 11???14 months) edara vone plus riluzole and riluzole only, even in the EESP.7 Such discrepancy is not uncommon; the design and conduct of trials on amyotrophic lateral sclerosis have been